Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 3213259 | [Effect of gold on lymphocyte stimulation by influenza A in chronic polyarthritis]. | 1988 May | In vitro stimulation with influenza-A antigens of the peripheral lymphocytes from patients with rheumatoid arthritis is significantly higher than that in those from healthy controls. Stimulation was performed without autologous serum, is dependent on the monocyte function and correlates with disease activity. Gold compounds can inhibit monocyte function and so the lymphocyte stimulation by influenza-A antigens. Cortico-steroids do not do this. Under gold compound treatment, lymphocyte stimulation was markedly reduced in about 70% of cases and was correlated with clinical success. | |
| 3498211 | The frequency of rheumatoid arthritis among relatives of probands with definite ankylosing | 1987 | We studied families of 23 unrelated HLA-B27 positive probands with definite ankylosing spondylitis to investigate the occurrence of rheumatoid arthritis. The prevalence of RA among these relatives was significant higher (2.91%; 0.02 less than p less than 0.05) than in the control group of 28 healthy individuals (1.02%). These data suggest an increased relative risk of RA in relatives of patients with AS. | |
| 2775318 | Involvement of nonarticular cartilage, as demonstrated by release of a cartilage-specific | 1989 Sep | Analysis of human cartilage extracts by radioimmunoassay showed that the noncollagenous 148-kd cartilage matrix protein was present in extracts of tracheal cartilage but was undetectable in normal or arthritic joint cartilage, corroborating previous results with bovine cartilage samples. Concentrations of the protein in the circulation, as studied by radioimmunoassay, were greatly elevated in patients with rheumatoid arthritis and polyarticular juvenile rheumatoid arthritis. In contrast, patients with reactive arthritis and oligoarticular juvenile rheumatoid arthritis, as well as rheumatoid arthritis patients treated with low-dose glucocorticoids, had levels similar to those in healthy controls. The serum concentrations were not related to age. A patient with polychondritis and tracheal involvement had a high serum concentration of the protein, which decreased during plasma exchange and cyclophosphamide treatment. Studies of the release of this cartilage matrix protein, which is present in nonarticular cartilage but not in articular cartilage, should aid in the understanding of the mechanisms of cartilage involvement in disease, and the protein may become a clinically useful marker. | |
| 3388993 | [Serum hyaluronic acid and aminoterminal procollagen III peptide in inflammatory and degen | 1988 Mar | Serum levels of hyaluronic acid (HA) and the amino-terminal type III procollagen peptide (NP-III-P) were determined simultaneously by specific immunoassays in patients with rheumatoid arthritis (n = 41), osteoarthritis (n = 43), ankylosing spondylitis (n = 7), psoriatic arthritis (n = 6), and reactive arthritis (n = 6). Increased serum levels of both HA and NP-III-P, were found in rheumatoid arthritis and - although less pronounced - in osteoarthritis, differing significantly from age- and sex-matched controls (n = 77). Furthermore, patients suffering from active rheumatoid arthritis showed higher serum levels of both antigens than patients with inactive disease, and significant correlations were found in rheumatoid arthritis between acute phase plasma proteins, HA and NP-III-P, respectively. In contrast, determination of low molecular weight fractions of NP-III-P by Fab- assay proved not to be useful in regard to clinical application. No significant effects of anti-inflammatory treatment were evident in any of the parameters. In rheumatoid patients, the serum concentrations of HA were found to correlate positively with the serum reactivity of NP-III-P related antigens (r = 0.692) and with the excretion of urinary pyridinoline (r = 0.455). Thus, both parameters seem to reflect similar mechanisms of connective tissue activation and may be related to inflammatory activity in joint diseases. | |
| 3241175 | Septic polyarthritis and its relation to systemic disease processes. A report of three cas | 1988 | In the case of a postoperative joint infection, the orthopaedic surgeon is frequently blamed. Certain intrinsic disease processes, however, make a joint more susceptible to infection. In these three reports of septic polyarthritis, all patients had underlying systemic disorders, including rheumatoid arthritis, diabetes mellitus, and hemophilia A. Two of the three patients had had no recent surgical procedures. This suggests that the development of a pyarthrosis may depend at least as much on the patient's underlying systemic condition as on the surgeon and his or her technique. | |
| 2718598 | [Late synovectomy of the elbow and resection of the radius head in chronic polyarthritis]. | 1989 Jan | Between 1974 and 1984 16 patients with rheumatoid arthritis, who had elbow synovectomy and excision of the radial head, were revised with an average follow-up of 5 years after operation. Resection of the radial head was performed on 16 elbows, in 3 elbows the ulnar nerve was transposed. The indication for the operation were pain, swelling, warmth and radiological destruction. The parameters used, to assess efficacy of the operation were range of motion, local finding and patient satisfaction. Synovectomy results were good especially in respect of relief of pain and range of motion. The good results justify elbow synovectomy even in the late stages of disease. | |
| 1883703 | Osteonecrosis. | 1991 Jun | Osteochondritis dissecans has been shown to heal with protective weight bearing alone, if there is no loose body in the joint. Magnetic resonance imaging can accurately predict the presence and extent of chondral fragments, and it appears that a magnetic resonance staging classification has been developed that allows preoperative staging of lesions of the talus and the knee. In a large study of hip dislocations, the most important predeterminant of poor clinical outcome was the presence of avascular necrosis. In addition to stigmata of rheumatoid arthritis, recognizable in 90% of 107 femoral heads in rheumatoid arthritis patients, 29 heads (28%) had intracapital trabecular fractures that were either the sole feature or a very important feature of the histopathology. In systemic lupus erythematosus patients the mean maximal daily dose of prednisone was significantly greater in patients with osteonecrosis than in those without bony complications. A novel canine model allowing investigations into the pharmacologic regulation of circulation in bone is discussed along with the first demonstration in humans of a pharmacologically produced decrease in bone marrow pressure. In spontaneous osteonecrosis of the knee, patients with magnetic resonance abnormalities on T2-weighted images have a poor clinical outcome. Magnetic resonance imaging of the hip can provide images of equal resolution in any plane, which is helpful in evaluating the extent and location of femoral head involvement. A large study revealed that total joint replacement should be done judiciously in osteonecrosis, because there is a 37% overall failure rate as compared to 10% failure rate in total hip replacements done for other causes.(ABSTRACT TRUNCATED AT 250 WORDS) | |
| 3551606 | Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate thera | 1987 Apr | To determine if long-term methotrexate-induced improvement of rheumatoid arthritis is sustained after the drug is discontinued, 10 unselected patients with responses to weekly oral methotrexate given for at least 36 months (mean 40.1) were randomly assigned to receive methotrexate or identical-appearing placebo tablets for two months. After one month, all five patients receiving placebo had to have the study terminated due to a flare of their disease manifested by statistically significant deterioration in multiple clinical parameters. It is concluded that patients receiving long-term methotrexate must continue the drug to maintain clinical benefits. | |
| 2237677 | [Clinical studies on 9 patients with Heberden's nodes of premenopausal onset]. | 1990 Apr | Nine patients with Heberden's nodes of premenopausal onset were studied for complications in the form of thyroid disorders as well as from the hereditary, roentgenological and immunological aspects. In addition, rheumatoid arthritis, psoriatic arthritis, traumatic arthritis, erosive osteoarthritis or adult Still's disease was excluded in these patients. All patients had thyroid disorder (Basedow's disease in 6 patients, Hashimoto's thyroiditis in 2 patients and granular thyroiditis in one patient). Immunological examinations were positive for anti-thyroglobulin antibody in 5 patients and anti-microsome antibody in 3 patients and anti-nuclear antibody in 2 patients. Roentgenological findings revealed no typical signs of primary generalized osteoarthritis. | |
| 3704507 | [Liver complications caused by D-penicillamine. Apropos of a case]. | 1986 Jan | The complications of D-penicillamine are rare. It generally consists of reversible cholestatic hepatitis which may, however, be fatal. The authors report a typical case with a benign outcome and with concomitant signs of cutaneous intolerance with eosinophilia. The definite role of D-penicillamine was confirmed by the re-introduction of the drug. | |
| 3319968 | [Penicillamine-induced pemphigus]. | 1987 Sep | D-Penicillamine is effective in the treatment of Wilson's disease, cystinuria and rheumatoid arthritis. However, it may have adverse side-effects by inducing a spectrum of diseases such as myasthenia gravis, lupus-like disease, IgA deficiency and pemphigus vulgaris. A case of D-penicillamine-induced pemphigus is presented. The clinical aspects, pathogenesis, immunology and therapy of D-penicillamine-induced diseases are discussed. | |
| 3593433 | Monocyte Fc receptor function in rheumatoid arthritis. Enhanced cell-binding of IgG induce | 1987 May | Monocytes from 11 patients with rheumatoid arthritis and 10 control subjects were purified by countercurrent elutriation. Rheumatoid arthritis monocytes had more cell-associated IgG (P less than 0.001) and bound more 125I-labeled heat-aggregated IgG in vitro (P less than 0.02) than did monocytes from control subjects. Interaction of rheumatoid factor (RF) with monocytes was then investigated. Purified 125I-labeled IgM-RF and IgG-RF bound directly to monocytes from normal individuals. Furthermore, preincubation of normal monocytes with RF augmented subsequent binding of aggregated IgG to the cells. We conclude that monocyte-associated RF can enhance binding of IgG-containing immune complexes to the cells and can exaggerate the measured number of Fc receptors. Such cell-bound RF may affect clearance of immune complexes by the reticuloendothelial system in vivo. | |
| 2421905 | Immunomodulation of neutrophil chemotaxis in rheumatoid arthritis using levamisole and met | 1986 | The inflammatory process of rheumatoid arthritis is characterized by an alteration in neutrophil function and an accompanying increase in the number of these cells within the joint space. Both inhibition of peripheral neutrophil chemotaxis and the paradoxic and concomitant deleterious effects of overreactive synovial neutrophils are expressions of an imbalance within the immune system. Levamisole and methisoprinol have been found to improve the alterations in cellular function and immune response. We studied the in vitro effect of these drugs on neutrophil function in four patients with rheumatoid arthritis whose basal chemotaxis was seriously inhibited. Levamisole and methisoprinol improved neutrophil chemotaxis by inducing, in monocytes incubated with these drugs, the production of an important chemotactic factor effective on the altered neutrophils. We suggest that the use of these drugs is beneficial in the treatment of rheumatoid arthritis. | |
| 3150923 | Rheumatoid arthritis: an editorial perspective based on cytokine imbalance. | 1988 Aug | Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) are distinct systemic rheumatic and autoimmune diseases with overlapping clinical features and laboratory findings. Although the majority of patients fit the textbook descriptions of these disorders, there are occasional patients whose illness defies precise diagnostic classification. Examples are mixed connective tissue disease, rheumatoid arthritis and systemic vasculitis, and the overlap SS/SLE syndrome with anti-Ro autoantibodies [1]. Cytokine abnormalities are prominent in all rheumatic diseases. This editorial focuses on cytokine abnormalities in RA and particularly in the rheumatoid synovium, but because of these disease interrelationships has implications for SS and SLE as well. The pathology in RA can be dominated by the systemic features, particularly when rheumatoid lung, severe vasculitis or Felty's syndrome are present. Rheumatoid factor was the first autoantibody to be extensively studied from functional, pathological and immunogenetic aspects. For most patients, however, joint inflammation with its predilection to progress to joint destruction comes to dominate the clinical picture. For the clinical immunologist, the ability to study synovial fluid and cells offers an investigative opportunity not generally found in other rheumatic diseases, i.e. to take measurements where the action is, directly at the site of autoimmune attack. Careful histopathologic studies performed decades ago are the basis for our understanding of immunopathogenic events in the rheumatoid synovium. These studies highlight the intense chronic inflammatory activity with activated macrophages, lymphocytic and plasma cell infiltration, germinal center formation, and tissue destruction. Local production of rheumatoid factor and immune complexes, as well as complement consumption, were demonstrated 20 years ago in an investigative era dominated by humoral immunity.(ABSTRACT TRUNCATED AT 250 WORDS) | |
| 1689161 | Substance P and arthritis: analysis of plasma and synovial fluid levels. | 1990 Jan | The uncadecapeptide substance P (SP), which is localized in peripheral and central terminals of afferent nerve fibers with polymodal nociceptors, has recently been implicated as having a neurogenic, inflammatory role in experimental arthritis. We used a radioimmunoassay to measure SP levels in plasma and synovial fluid samples from patients with rheumatoid arthritis (RA), osteoarthritis (OA), Reiter's syndrome (RS), and posttraumatic arthritis, as well as in plasma samples from 13 normal subjects. Plasma SP levels in RS patients exceeded levels in RA and OA patients, which in turn exceeded levels in posttrauma patients and in normal subjects. Synovial fluid SP levels exceeded respective plasma levels for all groups, except in RS patients, in whom the plasma level was not significantly different from that in synovial fluid. SP levels in synovial fluid of RA, OA, and RS patients did not differ significantly from each other, but the level in posttrauma patients was higher than in all other groups (P less than 0.005). These studies demonstrate localized intraarticular SP release, and significant plasma/synovial fluid SP concentration gradients in several forms of arthritis. | |
| 3321209 | Biochemical mechanisms of articular destruction. | 1987 Aug | The destruction of articular structures in inflammatory arthritis is a complex process. Both proteolytic degradation of the individual structural proteins that make up the tissues of the joint as well as nonproteolytic processes, such as bone demineralization are involved. Proteinases that can degrade collagen and proteoglycans are present in the various cells that comprise the rheumatoid lesion. Neutrophils contain collagenolytic metalloproteinases (collagenase and gelatinase) as well as potent serine proteinases (elastase and cathepsin G). Synovial cells and chondrocytes secrete metalloproteinases, which are also capable of degrading the extracellular matrix. Evidence would support the concept that the regulatory and counter-regulatory factors that govern the activity of these enzymes are abnormal in inflammatory arthritis, resulting in articular destruction. | |
| 2088648 | Antibodies to cardiolipin and intermediate filaments: a study of autoimmunity in rheumatoi | 1990 Dec | Autoantibodies to cardiolipin and intermediate filaments have both been reported with increased frequency in rheumatoid arthritis. We evaluated the frequency, pathological significance, and diagnostic relevance of these autoantibodies in a series of 124 patients and controls. We studied 81 patients with rheumatoid arthritis, 23 with osteoarthritis, and 20 normals. Antibodies to cardiolipin were measured by an ELISA method and antibodies to intermediate filaments were measured by indirect immunofluorescence using HEp2 cells. Antibodies to cardiolipin were present in 58% of rheumatoid patients and antibodies to intermediate filaments were present in 55% rheumatoid patients. They were both predominantly of IgM class, and were more frequent than in normal or osteoarthritic controls. Correlating levels of both these autoantibodies to clinical and laboratory measures of disease activity such as Ritchie articular index and C-reactive protein level showed that no consistent relationships existed. They were not related to other auto-antibodies such as rheumatoid factors and anti-nuclear antibodies, nor to each other. These results show that antibodies to cardiolipin and intermediate filaments in rheumatoid arthritis are of no diagnostic value, they are not related to disease activity, and have no relationship to other autoimmune disturbances. We suggest that several pathological mechanisms must be involved in the development of autoantibodies in rheumatoid arthritis. | |
| 3018908 | Superoxide generation by synovial fluid neutrophils enhanced by immune complexes and suppr | 1986 | Synovial fluid (SF) from patients with rheumatoid arthritis (RA) enhanced superoxide generation by neutrophils isolated from RA SF, in contrast to SF from patients with osteoarthritis. These superoxide generation-enhancing substances may be intermediate-sized immune complexes and a complement C5-derived fragment. Rheumatoid factor (RF) isolated from RA SF suppressed superoxide generation-enhancing activity of aggregated IgG. Therefore, biologically active RF may block the interaction of the immune complexes with neutrophils accumulating in RA SF, and protect the joint tissue from the effects of oxygen radicals or proteases. | |
| 2182853 | Methodology issues in the evaluation of NSAID in inflammatory rheumatic diseases. | 1990 Feb | The characteristics required of tests used in trials of nonsteroidal antiinflammatory drugs in patients with inflammatory rheumatic diseases in order for such tests to provide meaningful results are reviewed. Those tests most widely used in trials of patients with rheumatoid arthritis or ankylosing spondylitis are assessed, and the ability of such tests to discriminate among the treatment effects of different agents is considered. Finally, several statistical and procedural issues important to clinical trial methodology are discussed. | |
| 3690986 | Longterm results of auranofin therapy. | 1987 Sep | The results of longterm therapy with the oral gold preparation auranofin in patients with rheumatoid arthritis (RA) were evaluated based on the following data: 1) Two multicenter open uncontrolled studies (MTC06) and (162EMUA-RA), 2) the reevaluation of these data for the MTC06 study after 4 years from the beginning of the study and 3) the results of a postmarketing surveillance program (PMSP) of patients on auranofin therapy. The specific rheumatologic documentation and information system (IKR inhaltkodierte rheumatologic) serves as the basis of the follow-up studies and longterm observations. The first year data on 207 patients (MTC06) indicating that duration of the disease less than 2 years was the only discriminating factor regarding a positive treatment outcome were confirmed by the two-year (151 patients). Patients, who responded favourably to Auranofin did usually well for the four-year or longer observation period. The data base of these two studies and the PMSP failed to outline any new severe or threatening side effects. Diarrhea and loose stools were more common at the beginning of the treatment. The overall withdrawal for untoward events was 11.2%. Patients who did or did not respond to previous DIMARD therapy either on i.m. gold, D-Penicillamine or Chloroquine, did usually well when treated with Auranofin, even if severe side effects leading to withdrawal had occurred on previous therapy. The favourable safety profile was confirmed by the PMSP data. |